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miR-1254 and miR-574-5p
Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell
Lung Cancer
Kristen M. Foss, BS,* Chao Sima, PhD,* Donatella Ugolini, BS,†‡ Monica Neri, PhD,§
Kristi E. Allen, BS,* and Glen J. Weiss, MD*
Introduction: The ability to diagnose non-small cell lung cancer
(NSCLC) at an early stage may lead to improved survival. The aim
of this study was to identify differentially expressed serum-based
microRNAs (miRNAs) between patients with early-stage NSCLC
and controls. These miRNAs may serve as biomarkers for NSCLC
early detection.
Methods: miRNA profiling was performed on total RNA extracted
from serum obtained from 22 individuals (11 controls and 11 patients
with early-stage NSCLC). Quantitative polymerase chain reaction
(qPCR) was used to validate the profiling results in the discovery set
and in a validation set of 31 controls and 22 patients with early-stage
NSCLC. Additionally, six matched plasma samples (four NSCLC cases
and two controls) and three serum mesothelioma samples were ana-
lyzed by qPCR. Receiver operating characteristic curves were gener-
ated for each possible combination of the miRNAs measured by qPCR.
Results: The expression of hsa-miR-1254 and hsa-miR-574-5p was
significantly increased in the early-stage NSCLC samples with
respect to the controls. Receiver operating characteristic curves
plotting these two miRNAs were able to discriminate early-stage
NSCLC samples from controls with 82% and 77% of sensitivity and
specificity, respectively, in the discovery cohort and with 73% and
71% of sensitivity and specificity, respectively, in the validation
cohort. The mesothelioma and plasma samples did not seem to
classify into either NSCLC or control groups.
Conclusions: Serum miRNAs are differentially expressed between
patients with early-stage NSCLC and controls. The utility of miR-
1254 and miR-574-5p serum-based biomarkers as minimally inva-
sive screening and triage tools for subsequent diagnostic evaluation
warrants additional validation.
Key Words: MicroRNAs, Biomarker, Early-stage disease, Non-
small cell lung cancer, Early detection.
(J Thorac Oncol. 2011;6: 482–488)
Lung cancer is the most common cause of cancer-relateddeath in the world. In the United States, more than 90
million individuals are at risk for developing lung cancer, and
this disease is estimated to remain a major health problem for at
least the next 50 years. More than 75% of lung cancer cases are
diagnosed in late stages because there remains no practical way
to screen a large number of people at risk. This is the major
contributing factor to the dismal prognosis in non-small cell lung
cancer (NSCLC), which accounts for 85% of lung cancers.1
These results are clearly disappointing and point to the urgent
need for new strategies to help identify those at-risk individuals
that should be evaluated for this disease. Early detection offers
the promise of improved cure rates. The dilemma remains as to
how to efficiently facilitate stratification to appropriately identify
these individuals at high risk for developing NSCLC. For
NSCLC, broad application of computed tomography (CT)
screening to at-risk populations, based on clinical parameters
alone, has several drawbacks: (a) detection of significant rate of
benign lung nodules at a rate up to 50%2,3; (b) cost-benefit
analysis has projected that for every lung cancer death prevented
by CT screening, approximately two false-positive invasive
procedures will result4; (c) supply of adequately trained radiol-
ogists; and (d) coordination of appropriate follow-up and spe-
cialist referrals to investigate CT-detected abnormalities. Re-
view of recent CT screening studies shows that although lung
cancer diagnosis has increased more than threefold, the likeli-
hood for thoracic resection for lung cancer has increased 10-
fold.5 Furthermore, there seems to be no meaningful reduction in
the number of advanced cancers or the number of patients who
die of lung cancer. This raises concerns for the use of CT for
wide scale screening. Therefore, the need to find a less invasive,
more reliable biomarker is crucial to increase the probability of
earlier NSCLC detection and lower the risk of potential harm to
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truly make a difference in survival and at the same time, remain
both cost and resource utilization effective.
Blood serum is a minimally invasive, low risk, and easy
to obtain biofluid that can also be explored for potential
biomarkers. Serum-based microRNAs (miRNAs) have been
shown to be differentially expressed in various patients with
cancer, including NSCLC.6 Disease characterization has also
been demonstrated using miRNA expression profiling.7
These small noncoding RNAs of 21 to 25 nucleotides are
ideal for expression profiling compared with larger messen-
ger RNAs that are more susceptible to degradation6 and often
poorly overlap among various datasets.8
The aim of this study was to identify serum-based
miRNA biomarkers that discriminate early-stage NSCLC
from healthy individuals with a tobacco smoking history by
quantitative reverse transcription polymerase chain reaction
(qRT-PCR). The ability to identify patients with NSCLC
through a minimally invasive, potentially cost-effective man-
ner could lead to earlier detection of NSCLC and potentially
improved outcomes for these patients.
PATIENTS AND METHODS
Patient Samples
Serum and plasma samples from patients with (1)
early-stage NSCLC or (2) mesothelioma and (3) healthy
individuals (controls) with a history of smoking tobacco were
used in this study. Note: all samples collected from cancer
cases were done before initiation of cancer-directed therapy.
The discovery cohort consisted of serum samples from 11
controls and 11 patients with NSCLC. The validation cohort
consisted of serum samples taken from 22 patients with
NSCLC and 31 controls. Additionally, serum from three
early-stage mesothelioma patients and a total of six plasma
samples from both discovery and validation cohorts (four
NSCLC and two controls) were also available for analysis
(Table 1). All samples were acquired from the Cancer of
RESpiratory Tract biorepository under a standard protocol
described elsewhere.9 Appropriate informed consent was ob-
tained and institutional review board approvals were in place.
RNA Extraction and Cel-miRNA Spike in
Total RNA was isolated from a volume of 75 to 200 l
of serum or plasma using phenol and guanidine thiocyanate.
A total of 2 ng of cel-miR-39 was spiked into each sample10,11
after the addition of the phenol and guanidine thiocyanate to
serve as an external processing control.
miRNA Microarray Profiling
A minimum of 100 ng of total RNA from the discovery
cohort was added to the GenoExplorer microRNA Expression
System (GenoSensor Corporation, Tempe, AZ) containing
TABLE 1. Clinical and Demographic Characteristics of Subjects in Discovery and Validation Cohorts
Discovery Cohort Validation Cohort
Control NSCLC Control NSCLC Mesothelioma
No. of cases 11a 11 31b 22 3
Median age, yr (range) 64 (60–74) 65 (50–72) 62 (39–91) 62 (52–77) 69 (62–76)
Gender
Male 11 10 25 19 2
Female 0 1 6 3 1
Smoking history
Never smoker 1 0 0 1 1
Current smoker 5 6 11 6 1
Former smoker 5 5 20 15 1
Median pack years (range) 23.5 (0–46.5)c 42 (4.35–71.25) 44 (18–65) 42.5 (0–112.5)d 38 (0–46)
Stage
I NA 4 NA 6 1
I/II NA 0 NA 10e 0
II NA 6 NA 4 2
Unavailable NA 1 NA 2 0
Histology
Adenocarcinoma NA 6 NA 10 NA
Bronchioloalveolar carcinoma NA 1 NA 2 NA
Squamous cell carcinoma NA 1 NA 6 NA
Large cell carcinoma NA 1 NA 2 NA
Other NA 1 NA 1 NA
Unavailable NA 1 NA 1 NA
a Two cases have two replicates that were treated as separate samples in the analysis.
b One case was diagnosed with bladder cancer at the end of 2009, 1.5 yr after sample collection.
c Subject with 0 pack years has smoked four cigars a day for 30 yr.
d Missing data for two cases.
e T2N0, no subclassification for T2a or T2b available. Therefore, cannot distinguish whether stage I or II.
NA, not applicable; NSCLC, non-small cell lung cancer.
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probes in triplicate for 880 mature miRNAs (Sanger miRNA
Registry version 13, September 2008) and 473 premiRNAs
along with positive and negative control probes. SAM data
analysis was applied to find significantly differentially ex-
pressed miRNAs in one condition in contrast to the other.
Data were normalized to PC-U6B, U6-337, 5S-rRNA, and
PC-HU5S. The top differentially expressed mature miRNAs
in serum from patients with NSCLC versus controls were
selected based primarily on fold change more than 1.54,
followed by p values, q values, and false discovery rates.
qRT-PCR Analysis of miRNAs
qRT-PCR was performed on the selected miRNA can-
didates to validate the miRNA array results. The GenoEx-
plorer miRNA First-Strand cDNA Core Kit (2002-50,
GenoSensor Corporation) was used to generate miRNA
first-strand complementary DNA. miRNA expression lev-
els were measured using SYBR Green (04887352001;
Roche; Indianapolis, IN). miRNA-specific forward primers
and a universal reverse primer were purchased (GenoSen-
sor Corporation). The reaction conditions were 15 minutes
of denaturation at 94°C followed by 45 cycles of 94°C for
30 seconds, 59°C for 15 seconds, and 72°C for 30 seconds.
Melting curve analysis was used to assess the specificity of
the amplified product. All qRT-PCR reactions were carried
out in triplicate on the Lightcycler 480 (Roche). miRNA
expression was normalized to the expression of RNU6 and
cel-miR-39 separately. We normalized using a variation of
the “delta” method. Specifically, if the Cp values for a
miRNA and the normalizer are C1 and C0, respectively, the
normalized value for C1 is 1  (C1  C0)/maxCp, where
maxCp is the number of maximum cycles.
qRT-PCR Data Analysis
A logit regression model was fit on the PCR data with
the predictors being one or more miRNAs (a predictor set,
therefore, comprises different combination of miRNAs). For
each logit classifier using a predictor set, a receiver operating
characteristic (ROC) curve was plotted, and area under the
curve (AUC) was computed. The best sensitivity/specificity
pair is selected as the highest specificity with sensitivity being
at least 0.6. p values for the predictor set using t statistical test
and Mann–Whitney–Wilcoxon test are also computed using
coefficients obtained from logit regression.
RESULTS
RNA Extracted from Human Samples
The 24 available samples from the discovery cohort had
a median of 352 ng total RNA (range:  147–1762 ng)
derived from 200 l serum and proceeded to miRNA mi-
croarray profiling and subsequent qRT-PCR analysis. Base-
line characteristics for the discovery cohort are listed in Table
1. The median age was 64 and 65 years for controls and
NSCLC, respectively. Nearly all were men, and all but one
individual (control no. 2678) had a history of tobacco smok-
ing in both groups. The median follow-up time for the
discovery cohort controls was 33.4 months (range: 27.4–
114.9 months). The majority of the discovery cohort NSCLC
cases were adenocarcinoma. Samples for the validation co-
hort became available for analysis at a later date. The 53
serum samples from the validation cohort had a median of
870 ng total RNA (range  410–3796 ng) derived from 100
to 200 l serum and proceeded to qRT-PCR analysis. Base-
line characteristics for the validation cohort are listed in Table
1. In both controls and NSCLC, the median age was 62 years,
with a majority of men, and nearly all had a documented
history of tobacco smoking. The median follow-up time for
the validation controls was 40.9 months (range: 8.8–108.5
months). Adenocarcinoma was the most common NSCLC
histology in the validation cohort. Total RNA was also
extracted from the three serum samples from early-stage
mesothelioma patients and six plasma samples from NSCLC
and control for qRT-PCR analysis. Detailed baseline clinical
characteristics for all samples are shown in Supplementary
Table 1 (http://links.lww.com/JTO/A57).
miRNA Profiling Analysis Reveals Differentially
Expressed miRNAs
miRNA profiling was performed on 24 samples of the
discovery cohort (including two separate serum samples from
control no. 1075 and control no. 1462). There were eight
miRNAs significantly (p value 0.05) differentially ex-
pressed by microarray, and four of the top 25 mature miR-
NAs had fold change more than 1.54. Because none of the top
hits had false discovery rate less than 0.05, we proceeded to
test the four mature miRNAs with fold change more than 1.54
between the patients with NSCLC and the controls to allow
for greatest distribution to stratify between the two groups
when proceeding to qRT-PCR measurement (Table 2). None
of the candidate miRNAs were significantly down-regulated
in early-stage NSCLC. To avoid overfitting, we intentionally
did not consider a larger signature due to the sample size.
Validation of miRNA Array Findings by qRT-
PCR in Discovery Cohort
The four miRNAs identified by array profiling were
measured by qRT-PCR in the discovery cohort. All possible
TABLE 2. miRNA Array Results
miRNA Ratio LCS/CS Median p FDR q Value
Hsa-miR-1268 2.22 0.06 0.28 0.12
Hsa-miR-574-5p 2.17 0.04 0.22 0.12
Hsa-miR-1254 1.62 0.21 0.42 0.12
Hsa-miR-1228* 1.54 0.20 0.45 0.12
Hsa-miR-297 1.43 0.03 0.30 0.12
Hsa-miR-1225-5p 1.39 0.01 0.31 0.12
Hsa-miR-923 1.23 0.03 0.24 0.12
Hsa-miR-1275 1.23 0.04 0.25 0.12
Hsa-miR-185 1.16 0.01 0.57 0.12
Hsa-miR-483-5p 1.13 0.03 0.26 0.12
Hsa-miR-320a 1.10 0.02 0.36 0.12
Median signal intensity normalized to the expression of PC-U6B, U6-337, 5S-
rRNA, and PC-HU5S was used for analysis. miRNAs in bold were selected for qPCR
validation.
LCS, lung cancer serum; miRNA, microRNA; CS, control serum; FDR, false
discovery rate; qPCR, quantitative polymerase chain reaction.
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combinations of these four miRNAs were plotted on ROC
curves to determine the combination that would stratify the
patients with the highest sensitivity and specificity. The best
set of predictors included two miRNAs, hsa-miR-1254 (miR-
1254) and hsa-miR-574-5p (miR-574-5p), that were differ-
entially expressed between the controls and stage I to stage II
NSCLC patient samples (p values of 0.016 and 0.0277 with
t statistical test and Mann–Whitney–Wilcoxon test, respec-
tively) with an AUC of 0.77 and can achieve 82% and 77%
for sensitivity and specificity, respectively (Figure 1). This
data suggest the existence of significantly differentially ex-
pressed serum-based miRNAs between patients with NSCLC
and controls.
Measuring miRNA Biomarkers in a Validation
Cohort
Expression of miR-1254 and miR-574-5p was mea-
sured in the serum from 53 NSCLC and control cases. When
normalized to cel-miR-39, the ROC curve had an AUC of
0.75 and a 73% and 71% of sensitivity and specificity,
respectively (p values of 0.0123 and 0.0025 with t statistical
test and Mann–Whitney–Wilcoxon test, respectively) (Figure
2). Note: the results were normalized separately to RNU6 and
cel-miR-39, and the ROC curves show little difference be-
tween normalizing to RNU6 and normalizing to cel-miR-39
for both the discovery and validation cohorts with coefficient
of variation less than 10% (data not shown).
No differences were seen in the sensitivity or specificity
when applying miR-1254 and miR-574-5p classifiers to ad-
enocarcinoma or gender-specific analysis (data not shown).
Expression of miR-1254 and miR-574-5p was also measured
in the serum of three early-stage mesothelioma cases. The
available plasma from four NSCLC and two controls did not
consistently classify into either the serum NSCLC or the
serum control group (data not shown).
DISCUSSION
The main result of this study is that miRNAs are
differentially expressed between patients with early-stage
NSCLC and controls. In particular, the expression of hsa-
miR-1254 and hsa-miR-574-5p was significantly increased in
early-stage NSCLC serum samples with respect to the con-
trols and could be detected even months before clinical
diagnosis. The combination of these two miRNAs may be a
useful biomarker for early diagnosis and a handy tool when
screening large numbers of high-risk individuals.
In addition, we confirm that miRNAs can be measured
from a relatively small amount of serum.10
Approximately 186,000 new NSCLC cases are diag-
nosed annually in the United States, and approximately
140,000 will be diagnosed with late-stage disease. To make
any dramatic impact to improve survival, identification of
high-risk individuals (primarily those with tobacco smoking
history) is sorely needed. Wide-based population screening
using general clinical risk factors alone has several significant
drawbacks including high-false positives, cost, supply of
trained health care staff, follow-up, and associated procedural
and psychological morbidities. Initial triage for image-based
evaluation using other minimally and/or noninvasive testing
may be the key to alleviating some of these drawbacks.
FIGURE 1. miR-1254 and miR-574-5p receiver operating
characteristic (ROC) curve for discovery cohort. Quantitative
polymerase chain reaction (qPCR) expression of miR-1254
and miR-574-5p was best able to stratify patients with early-
stage non-small cell lung cancer (NSCLC) from controls with
an area under the curve (AUC) of 0.77 and a 82% and 77%
of sensitivity and specificity, respectively. Data were normal-
ized to expression of cel-miR-39.
FIGURE 2. miR-1254 and miR-574-5p receiver operating
characteristic (ROC) curve for validation cohort. Curves were
generated from quantitative polymerase chain reaction
(qPCR) microRNA (miRNA) data normalized to cel-miR-39.
Stratification of early-stage non-small cell lung cancer
(NSCLC) and controls was achieved with a sensitivity and
specificity of 73% and 71%, respectively. The area under the
curve (AUC) is 0.75, and the model is correctly classified for
16 of 22 NSCLC cases and 22 of 31 control cases.
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Several groups have explored other modalities for bi-
omarker utility as a potential early-detection screening tool
for NSCLC. We selected studies reporting evaluation of
biomarkers for early detection of lung cancer and validation
in an independent cohort or miRNA biomarkers for early
detection of lung cancer (Table 3). All these studies have
certain limitations including sample size and detailing the
clinical follow-up time for evaluated control samples. Some
of these studies included patients with stage III or IV NSCLC
or even small cell lung cancer patient samples. Samples
analyzed spanned from blood, peripheral blood mononuclear
cells, sputum, serum, to large airway epithelial cells. The type
of biomarkers explored included miRNA, messenger RNA,
protein, or single-nucleotide polymorphisms. Limitation for
most of these studies, including ours, is the lack of validation
of the biomarker classifier in a sample set collected from a
biorepository separate and independent from where the dis-
covery samples were deposited. Another limitation for most
of these studies is a lack of documentation of the follow-up
time for samples collected from control subjects. As most
controls tend to be clinically matched to the NSCLC cases,
they also have the potential risk to develop NSCLC at a later
date. Misclassification of a sample because of inadequate
follow-up can potentially impact the utility of the biomarker
classifier. All together, our control samples had a median
follow-up time of 39.1 months, without developing NSCLC.
The Cancer of Respiratory Tract biorepository is able to
query the Italian tumor registry to identify potential misclas-
sifications months to years after the sample has been banked.
Samples banked months to years before an individual is
diagnosed with early-stage NSCLC are extremely valuable to
test the potential utility of a NSCLC biomarker as an early-
detection tool. This lead time information is often lacking
from early-detection biomarker studies. Two of the NSCLC
cases in our study were collected more than 8 months before
diagnosis, although true confirmation of early-stage disease is
not available. We acknowledge that our sample size for
discovery and validation is small, but compared with works
of others listed in Table 3, the number of stage I and stage II
NSCLC is similar or smaller to our sample size. It is impor-
tant to validate our classifier in a larger sample set of stage
I/II NSCLC and matched controls from an independent biore-
pository collection.
Only two studies in Table 3 reasonably describe the
source of their validation samples as derived from an inde-
pendent biorepository collection.12,13 Nevertheless, both
these studies fail to adequately describe the clinical charac-
teristics of their validation set,12,13 particularly the number of
early-stage NSCLC.12 This could impair the utility of apply-
ing these “meta-gene” classifiers to differentiate early-stage
NSCLC from controls.
In a majority of the studies, the number of biomarkers
proposed for further study total close to or more than the total
number of samples analyzed, which remains a concern for
data overfitting or attests to the minimal real contribution of
each individual biomarker among the entire classifier. For
example, Keller et al.14 used a 24 “meta-miR” support vector
machine classifier after trials of five different support vector
machine kernel functions and multiple feature sizes and
reported a sensitivity and specificity of 92.5% and 98.1%,
respectively. It is yet to be seen how this classifier performs
on an independent sample set.
The expression of miR-1254 is associated with early-
stage cancer for the first time in this study, whereas miR-
574-5p is listed as a differentially expressed miRNA in two
previous lung cancer miRNA publications.6,14 Our group has
also recently reported on miR-574-5p’s significant associa-
tion with chemoresistance in small cell lung cancer.15
Serum samples were available from three stage I to
stage II pleural malignant mesothelioma patients. Although
limited in number, these samples are highly valuable given
the rarity of this severe asbestos-linked cancer and the fact
that in the large majority of cases, mesothelioma is diagnosed
at late stages. Although very preliminary, our results suggest
that miR-1254 and miR-574-5p could not classify mesothe-
lioma to the same group as NSCLC. miRNA expression in
mesothelioma deserves new dedicated studies, as there is a
deep need of effective biomarkers to screen the cohorts of
asbestos exposed subjects at risk for mesothelioma.
Parallel plasma samples were analyzed in some sub-
jects, in addition to serum. Expression of miR-1254 and
miR-574-5p in plasma did not seem to differentiate between
early-stage NSCLC and controls. There was no difference in
the way the serum and plasma samples were processed for
RNA extraction or analyzed.
In conclusion, we propose the serum-based miR-1254
and miR-574-5p biomarkers for future application as mini-
mally invasive screening and triage tools for subsequent
diagnostic evaluation, after additional validation in samples
collected by other biorepositories.
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